Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biogen And Isis Join For Antisense Drug

by Rick Mullin
July 9, 2012 | A version of this story appeared in Volume 90, Issue 28

Biogen Idec and Isis Pharmaceuticals are joining to develop an Isis antisense drug for the treatment of myotonic dystrophy type 1, the most common form of muscular dystrophy in adults. Isis’ goal is to correct the underlying defect in the dystrophia myotonica-protein kinase (DMPK) gene that causes the disease. Isis will receive $12 million and is eligible for $59 million in milestone payments. Biogen Idec has the option to license the drug from Isis at any time before the completion of Phase II clinical trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.